Who is sponsoring NCT04654286?

NCT04654286 is sponsored by Dr. Soetomo General Hospital.

What drugs are being tested in NCT04654286?

Interventions in NCT04654286: Nerve transfer procedure, Nerve transfer with HAM-AdMSC composite wrapping.

What condition does NCT04654286 study?

NCT04654286 studies Brachial Plexus Neuropathies.

Is NCT04654286 still recruiting?

NCT04654286 is currently status unknown. Last updated 7 December 2020.

Last reviewed 2020-12-07 · How we verify

NCT04654286: BPI+MSC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Human Amniotic Membrane and Mesenchymal Stem Cells Composite

Status unknown NA Last updated 7 December 2020

What this trial tests

NA trial testing Nerve transfer procedure in Brachial Plexus Neuropathies in 24 participants. Status unknown.

Timeline

17 November 2016

Primary endpoint
30 July 2021

30 July 2022

Quick facts

Lead sponsor	Dr. Soetomo General Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	24
Start date	17 November 2016
Primary completion	30 July 2021
Estimated completion	30 July 2022
Sites	1 location across Indonesia

Drugs / interventions tested

Nerve transfer procedure
Nerve transfer with HAM-AdMSC composite wrapping

Conditions studied

Brachial Plexus Neuropathies — all drugs for Brachial Plexus Neuropathies →

Sponsor

Dr. Soetomo General Hospital

Who can join

Adults 15 to 55, any sex, with Brachial Plexus Neuropathies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical trial is to investigate the utility of composite wrapping comprising human amniotic membrane and allogeneic adipose-derived mesenchymal stem cells (HAM-AdMSC) for augmentation of nerve transfer procedure in upper TBPI patients

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Recent perspectives on the synergy of mesenchymal stem cells with micro/nano strategies in peripheral nerve regeneration-a review.
Sharifi M, Kamalabadi-Farahani M, Salehi M, Ebrahimi-Brough S, et al · · 2024 · cited 10× · PMID 39050683 · DOI 10.3389/fbioe.2024.1401512
Beyond conventional therapies: MSCs in the battle against nerve injury.
Song S, Li C, Xiao Y, Ye Z, et al · · 2025 · cited 3× · PMID 39896446 · DOI 10.1016/j.reth.2024.12.017
The Potential Role of Adipose-Derived Stem Cells in Regeneration of Peripheral Nerves.
Mohan SP, Priya SP, Tawfig N, Padmanabhan V, et al · · 2025 · cited 2× · PMID 39997654 · DOI 10.3390/neurolint17020023
Mesenchymal stem cells' "garbage bags" at work: Treating radial nerve injury with mesenchymal stem cell-derived exosomes.
Mushtaq M, Zineldeen DH, Mateen MA, Haider KH. · · 2024 · cited 2× · PMID 38817330 · DOI 10.4252/wjsc.v16.i5.467
Contemporary Strategies of Gene and Cell Therapy in the Treatment of Peripheral Nervous System Injuries and Disorders
Sharshakova A, Solovyeva V, Masgutova G, Fattakhova A, et al · · 2026
Peripheral nerve repair: innovations and future directions.
Aldali F, Tang L, Yang Y, Huang Y, et al · · 2026 · PMID 41634808 · DOI 10.1186/s12967-025-07567-z
Viewing Decellularized Amniotic Membrane Through the Lens of Coupled Scaffolding and Drug Delivery Systems in Regenerative Medicine.
Alibabaei-Omran F, Javanmehr N, Al-E-Ahmad A, Zabihi E, et al · · 2025 · PMID 40741540 · DOI 10.1155/term/8818058

Verify or expand the search:

Other Dr. Soetomo General Hospital trials

Trials by the same sponsor.

NCT06935630 — Comparison of The Effect of 5-MTHF and Folic Acid Supplementation in Increasing Red Blood Cell Folate in Pregnant Women · NA · recruiting
NCT06259578 — UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study) · EARLY_PHASE1 · unknown
NCT07328113 — Interleukin-6 and Thyroid Dysfunction in Hemodialysis Patients · completed
NCT06272253 — UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects · EARLY_PHASE1 · unknown
NCT06282692 — INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old · Phase 3 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04654286 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dr. Soetomo General Hospital
Last refreshed: 7 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04654286.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing